BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Aug. 27, 2021
View Archived Issues
Phase I study evaluates PGV-001-based personalized multipeptide vaccines for prostate cancer
Read More
Phase I trial of molecular targeted therapy with adoptive cell therapy for DIPG and neuroblastoma
Read More
XRad initiates phase Ia study of XRD-0394 with radiation therapy in advanced solid tumors
Read More
Foghorn Therapeutics discovers SMARCA2/SMARCA4 inhibitors
Read More
Cannabinoid CB1/CB2 receptor partial agonists patented by Research Triangle Institute
Read More
BioTheryX presents PROTACs including casein kinase I isoform alpha degradation inducers
Read More
Stressed fat cells send mitochondria to teach heart cells self-defense
Read More
Landos collaborates with Johns Hopkins to further validate NLRX1 immunometabolic pathway in MS
Read More
MKK-4 inhibition for liver regeneration
Read More
Airway initiates phase Ib trial of AT-100 in mechanically ventilated patients with COVID-19
Read More
Chinese clearance for phase Ib/III trial of afuresertib with fulvestrant in HR+, HER- breast cancer
Read More
Pardes initiates phase I study of antiviral PBI-0451 for SARS-CoV-2 infection
Read More
Unnatural Products targets MDM2 and MDM4 with macrocylic peptides
Read More
Data presented for Sage Therapeutics' SAGE-718 for neurological diseases
Read More
First-in-human study planned with NXP-800 in advanced cancers
Read More
Preclinical studies characterize bispecific EGFR/CD16A NK innate cell engager AFM-24
Read More
RubrYc enters license and collaboration agreements on epitope-targeted antibody therapeutics
Read More